Bayer’s Kerendia Study Hits Its Mark, but CEO Warns of Hormuz Fallout and Germany’s Cost Squeeze

Bayer shares ended the trading week at €35.95, a gain of 1.58% on Friday that left the stock hovering barely 0.41% above the 200-day moving average of €35.80. That technical crutch is about as thin as it gets — and the stock still sits below its 50-day moving average of €38.39. On a seven-day view the shares are down 1.45%, and since the start of the year they have fallen roughly 5%.

What gave the Friday session its lift was a late-breaking piece of medical news that strengthens the company’s pipeline story. A phase III trial dubbed FIND-CKD for the drug Kerendia (finerenone) met its primary endpoint, demonstrating a measurable slowing of disease progression in adults with non-diabetic chronic kidney disease. The primary measure was the estimated glomerular filtration rate, a standard gauge of kidney function, and the study also hit a statistically significant reduction in a secondary composite endpoint covering kidney failure, a sustained eGFR decline of at least 57%, hospitalisation for heart failure, and cardiovascular death. The data were unveiled as a late-breaker on 5 June at the 63rd Congress of the European Renal Association in Glasgow and published simultaneously in the New England Journal of Medicine — a double milestone that medical researchers regard as a stamp of validation. Kerendia is already approved for other indications, and the FIND-CKD results open a potential new market for the drug among patients with few existing treatment options. The next step is regulatory: Bayer must submit the data to health authorities to win an expanded label, and the speed and outcome of that process will determine the commercial payoff.

That pipeline win, however, landed in a week crowded with less encouraging headlines. In an interview published on 5 June via t-online, Bayer chief executive Bill Anderson delivered a blunt two-pronged warning. The first is geopolitical: roughly one-third of the world’s trade in nitrogen-based fertiliser passes through the Strait of Hormuz, and a sustained blockade there could produce significantly lower harvests across the northern hemisphere as early as this autumn. Bayer does not make fertiliser, but the knock-on effect runs straight through its core agribusiness — weaker harvests cut farmers’ incomes, and farmers buy fewer seeds. Crop Science, the company’s strongest division, grew sales by 6.8% to €7.558 billion in the first quarter of 2026, though some of that gain was temporary. A poor autumn harvest would put pressure on that division. Beyond seeds, a fertiliser shortfall for maize would cascade into animal feed shortages, pushing up meat and egg prices and clouding the broader agricultural outlook.

Should investors sell immediately? Or is it worth buying Bayer?

Anderson’s second warning was directed at Germany. He said electricity costs at home are more than triple those on the Texas Gulf Coast and more than double those in China, while high non-wage labour costs and swelling bureaucracy compound the disadvantage. The CEO sees no relief — only more reporting requirements and regulation. He called on Chancellor Merz to articulate a clear mission for reigniting innovation, but made it plain that Germany’s structural cost problem is a permanent drag on Bayer’s cost base, regardless of geopolitical events.

The most consequential near-term catalyst, though, is neither a pipeline study nor a CEO interview. JPMorgan expects a US Supreme Court ruling on the glyphosate litigation complex by the end of June, with a first opinion day already announced for 11 June. Roughly 80% of the outstanding lawsuits against Bayer are tied to that decision. For now, investors are left weighing a tangible pipeline advance against three headwinds — a legal reckoning, a geopolitical supply squeeze, and a domestic cost burden that the company’s own leader describes as unsustainable.

Ad

Bayer Stock: New Analysis - 7 June

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

en | DE000BAY0017 | BAYER’S | boerse | 69496647 |